The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low
In This Article:
Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment.